Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Berlin - Delayed Quote EUR

Oncopeptides AB (OND.BE)

0.1482

-0.0102

(-6.44%)

At close: April 4 at 7:35:18 PM GMT+2

Oncopeptides AB (FRA:OND) Q4 2024 Earnings Call Highlights: Strong European Sales Growth and ...

Oncopeptides AB (FRA:OND) reports a 35% increase in European sales and advances in key markets, despite facing challenges in France and Norway.

GuruFocus.com last month

ONCO.ST
Oncopeptides AB (STU:OND) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Market ...

Oncopeptides AB (STU:OND) reports increased revenue and cost efficiency, while navigating market challenges and focusing on key European markets.

GuruFocus.com 4 months ago

ONCO.ST
Oncopeptides expands on WODA partnership with addition of Africa and Eurasia to provide Pepaxti to Patients

ZURICH and ZUG, Switzerland and STOCKHOLM, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Veld Pharmaceuticals GmbH (“Veld”) and Slavpharma GmbH (“Slavpharma”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in Africa and Eurasia. Under the terms of this exclusive agreement, Veld and Slavpharma will distribute Pepaxti to patients in their respective regions f

GlobeNewswire 6 months ago

ONPPF

Performance Overview

Return	OND.BE	OMX Stockholm 30 Index (^OMX)
YTD	+11.09%	-7.89%
1-Year	-70.54%	-9.30%
3-Year	-84.18%	+7.06%